Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 1.00 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.53 |
| ▸ | TDP2 | O95551 | 2/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28758793 | 0.87 | KIF11 (0.77) | KIF11ERAP1NPY5RKDM1ABRD4 | |
| SCHEMBL17806557 | 0.86 | KIF11 (0.76) | KIF11KDM1ABRD4TDP2HSD17B1 | |
| SCHEMBL3374813 | 0.85 | KIF11 (0.74) | KIF11NPY5RHSD17B1HSD17B2 | |
| SCHEMBL5525973 | 0.85 | KIF11 (0.74) | KIF11ERAP1PFKFB3 | |
| SCHEMBL3380022 | 0.84 | KIF11 (1.00) | KIF11 | |
| SCHEMBL5133296 | 0.84 | KIF11 (0.72) | KIF11ERAP1KDM1APFKFB3NTRK1 | |
| SCHEMBL5133295 | 0.84 | KIF11 (0.72) | KIF11ERAP1KDM1APFKFB3NTRK1 | |
| SCHEMBL3565704 | 0.83 | KIF11 (0.70) | KIF11ERAP1NPY5RPFKFB3SYK | |
| SCHEMBL12313373 | 0.82 | KIF11 (0.69) | KIF11NPY5RBRD4 | |
| SCHEMBL21092440 | 0.82 | KIF11 (0.69) | KIF11KDM1ABRD4TDP2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | claimed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | claimed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | claimed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | KIF11 824/4885ERAP1 1267/4885NPY5R 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.